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Abstract 
Background: In patients with asthma, the fungus Aspergillus fumigatus can cause allergic bronchopulmonary asper-
gillosis (ABPA). Familial ABPA is reported, and some genetic factors have been associated with the disease, however, 
these are small studies (n ≤ 38) and do not explain all cases of ABPA.
Methods: We analysed SNPs in 95 ABPA patients, comparing frequencies to 152 atopic asthmatic and 279 healthy 
controls. Twenty two genes were selected from literature, and 195 tagging SNPs were analysed for genetic association 
with ABPA using logistic regression corrected for multiple testing. We also analysed monocyte-derived macrophage 
gene expression before and during co-culture with A. fumigatus.
Results: Seventeen ABPA-associated SNPs (ABPA v Atopic asthma) were identified. Three remained significant after 
correction for multiple testing; IL13 rs20541, IL4R rs3024656, TLR3 rs1879026. We also identified minor differences in 
macrophage gene expression responses in the ABPA group compared to the control groups.
Conclusions: Multiple SNPs are now associated with ABPA. Some are novel associations. These associations impli-
cate cytokine pathways and receptors in the aberrant response to A. fumigatus and susceptibility to ABPA, providing 
insights into the pathogenesis of ABPA and/or its complications. We hope these results will lead to increased under-
standing and improved treatment and diagnostics for ABPA.
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Background
The fungus Aspergillus fumigatus is ubiquitous and 
humans inhale several hundred conidia each day [1]. Most 
overtly immunocompetent individuals clear A. fumiga-
tus conidia without infection or sequelae, however, some 
asthmatic patients develop allergic bronchopulmonary 
aspergillosis (ABPA) following inhalation and airway col-
onisation [1, 2]. The exact numbers affected is unclear, but 
if systemically sought, ABPA is identified in 1–8 % of asth-
matics seen in hospital referral clinics [3, 4]. Presentation 
usually involves poorly controlled asthma, wheezing, 
expectoration of brown mucus plugs, and ‘pneumonia’. 
Elevated total blood IgE levels and IgE reactivity to A. 
fumigatus is observed in patients, and A. fumigatus is 
often isolated from sputum [1]. Often central bronchiec-
tasis and mucoid impaction of bronchi with distal atelec-
tasis occurs. Untreated ABPA can result in pulmonary 
fibrosis and eventually respiratory failure [1].
The human immune response to A. fumigatus involves 
many cell types, including macrophages and neutro-
phils. These phagocytose and kill the fungus and produce 
chemotactic and proinflammatory cytokines to continue 
and orchestrate the immune response. As macrophages 
are present in the airways they may be the first innate 
immune cell to contact inhaled fungi.
In ABPA patients, an allergic Th2 response develops 
on exposure to A. fumigatus. Stimulation of PBMCs with 
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Aspergillus results in production of Th2 cytokines IL5 
and IL13, and ABPA patients show increased Aspergil-
lus-induced IL5 and IL13, and decreased IFNγ produc-
tion, compared to healthy controls [5]. IgE production, 
eosinophil recruitment, and production of an abnormal 
host inflammatory response in the bronchi and bron-
chioles of the lungs is observed [6]. This is followed by 
excessive mucin production, eosinophil infiltration of 
the bronchial mucin, and development of the features 
of ABPA [1]. Why some asthmatic individuals develop 
ABPA while others are unaffected by exposure to A. 
fumigatus remains unclear, despite studies. In unsensi-
tised mice, chronic intranasal administration of mould 
spores or extracts can lead to allergic lung inflammation, 
hyper-reactivity and lung remodelling [7], but the effect 
in humans is unclear. Cases of ABPA within families sug-
gest a common genetic basis with low penetrance [8, 9]. 
In one case series from India, 5  % of cases were found 
to be familial in nature [10]. The structural gene CFTR 
has been previously associated with ABPA [11], and 
small genetic association studies (involving ≤38 patients) 
have identified associations between ABPA and SNPs in 
the immune genes IL4R, IL10, TLR9, SFTPA2 and HLA 
(HLA-DR) [12–16], however, these results do not explain 
all cases of ABPA, and the immune mechanisms that 
underlie ABPA remain unclear.
To advance our understanding of immune responses 
and genetic susceptibility to ABPA, we conducted a 
much larger genetic association study, involving almost 
100 ABPA patients and using atopic asthmatic patients as 
controls, as well as a second control of healthy subjects. 
Candidate genes included known A. fumigatus recogni-
tion receptors (dectin-1, TLR2, TLR4 and TLR9 [17–20]) 
and other possible recognition receptors (TLR1, TLR3 
and TLR6 [21, 22]), downstream response genes, many of 
which are upregulated in response to A. fumigatus (IL1α, 
IL1β, IL1RN, IL1RAP, IL6, IL10, IL17A, TNF-α, CCL2, 
TGFB1, PTX3) [20, 23], mannose binding lectin (MBL) 
and plasminogen, both of which bind A. fumigatus [23, 
24], other Th1 (TNF-α, IL15) and Th2 (IL4, IL5, IL13, 
CCL17) cytokines [25, 26] and signal transducer and acti-
vator of transcription-3 (STAT3), which mediates IL-10 
anti-inflammatory functions in macrophages and neu-
trophils [27]. Other immune genes not previously inves-
tigated in Aspergillus infection, such as DENN/MADD 
domain containing 1B (DENND1B), a negative regula-
tor of the TNF-α receptor, and adenosine A2a receptor 
(ADORA2A) were also included [28]. In addition, we 
analysed expression of some of these immune genes in 
monocyte-derived macrophages (MDMs) at baseline 
and during co-culture with live A. fumigatus, comparing 




ABPA subjects, asthmatic controls and healthy controls 
were defined as described in Table  1. Both atopic (but 
fungally non-atopic) asthmatic and non-atopic asthmatic 
controls were recruited. ABPA subjects complicated 
by CCPA were excluded. Only Caucasian subjects were 
used. ABPA patients were recruited from the National 
Aspergillosis Centre [University Hospital of South Man-
chester (UHSM), UK] tertiary referral clinic from March 
2006 to August 2010. Previous recruited healthy and 
asthmatic subjects were used as controls [29, 30]. The 
Local Research Ethics Committee approved the study 
and all participants gave informed consent. The healthy 
control subjects have been used as controls for previous 
studies into genetic susceptibility to CCPA [31, 32].
DNA and PBMC extraction from blood
For DNA, blood was collected in EDTA-treated blood 
collection tubes (Becton Dickinson; BD, Oxford, UK). 
This was centrifuged to separate the plasma and cel-
lular sections and then DNA was then extracted from 
the cellular section using a phenol chloroform extrac-
tion method. Both the plasma and DNA were stored at 
−80 °C. For the previously recruited subjects, DNA had 
been collected previously [30].
For PBMC extraction, blood (≤80  ml) was collected 
in sodium heparin treated blood collection tubes (BD) 
then layered onto Ficoll-paque Plus (GE Lifesciences, 
Buckingham, UK) in a 1:1 ratio and centrifuged (23  °C, 
0.5 h, 480g). The PBMC layer was transferred into growth 
media (RPMI 1640 with l-glutamine and NaHCO3, with 
10  % heat inactivated FBS, 100  units/ml penicillin, and 
0.1 mg/ml of streptomycin [Sigma-Aldrich Company Ltd, 
Dorset, UK]) and centrifuged to pellet the PBMCs (24 °C, 
10  min, 390g). These PBMCs were frozen in freezing 
media [Heat inactivated FBS (Life Technologies Ltd, Pais-
ley, UK) with 5  % DMSO Hybri-max (Sigma-Aldrich)] 
at a concentration of ~1 ×  107 cells/ml. Frozen PBMCs 
were transferred to liquid nitrogen for long term stor-
age. Recovery and viability after freezing were assessed 
by trypan blue staining and found to be high (normally 
>90 %).
Gene and SNP selection, genotyping, quality control 
and data analysis
Twenty two biologically plausible and previously asso-
ciated candidate genes with immune functions were 
selected from the literature (Additional file 1: Table S1). 
These included genes involved in immune recognition 
and response, especially those involved in recognition 
and response to fungus specifically. It did not include the 
CFTR gene, which has structural functions.
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A total of 253 haplotype tagging SNPs within 
these genes of interest were selected for genotyping, 
using the Genome Variation Server (GVS, http://gvs.
gs.washington.edu/GVS/) (Additional file  1: Table  S1). 
These were usually selected to encompass the entire gene, 
plus 2500 bp up- and 1500 bp down-stream.
Genotyping was completed on 237 SNPs using the 
Sequenom® MassArray® iPLEX™ Gold system. SNPs 
with Hardy–Weinberg Equilibrium p  <  0.0001 or call 
rates <90 % were excluded from the analysis. After this, 
subjects with call rates <90  % were excluded from the 
analysis. Genotyping was completed in two rounds. In 
the first round, genotyping was completed successfully 
in 95 ABPA, 279 healthy and 152 atopic asthmatic sub-
jects; an additional 14 atopic asthmatic subjects were 
genotyped successfully in the second round. Results were 
analysed using SNP and Variation Suite (SVS; version 
7.4.3, Golden Helix). Redundant SNPs (r2  >  0.80) were 
excluded from analysis after evaluation of the LD within 
our population, as were SNPs that were monomorphic 
within our population. Statistical analysis was completed 
using Stata (Statacorp). Logistic regression was  used to 
determine association for the remaining 195 SNPs using 
dominant and recessive models. Atopic asthmatics were 
used as controls for this analysis. Correction for multi-
ple testing was completed using the Benjamini–Hoch-
berg correction for False Discovery Rate [33]. A p value 
of p < 0.05 was considered significant. The p values were 
calculated using the R software [34]. The widely used 
Benjamini–Hochberg correction for False Discovery Rate 
is less stringent than the Bonferroni correction in which 
p values are multiplied by the number of comparisons. 
The Benjamini–Hochberg correction for FDR is shown to 
have higher power compared to other procedures includ-
ing the Bonferroni method for multiple testing [35]. For 
SNPs associated with ABPA in the comparison to asth-
matic subjects, a genetic association test was completed 
to identify the p value for the comparison to healthy 
subjects.
Macrophage‑A. fumigatus co‑culture
Ten each of ABPA, non-atopic asthmatic and healthy 
subjects were selected for the macrophage-A. fumigatus 
co-culture experiment. MDMs were generated (approx. 
2 × 105/well), live A. fumigatus conidia added (4 × 105/
well) and RNA extracted as described previously [31]. 
Previous work shows that during the incubation period, 
proportions of the different fungal morphologies 
Table 1 Diagnostic criteria for recruited subjects
Disease Diagnostic criteria
ABPA All the following are required
Total serum IgE 1000 IU/ml (at any time)
Either positive SPT for Aspergillus or Aspergillus specific IgE
Current or historical evidence of eosinophilia
Further indicators
Almost all patients have asthma (or cystic fibrosis, n = 3) and over 50 % central bronchiectasis on CT, but these were not 
required for inclusion
Either recurrent obstruction (mucoid impaction) or episodes coughing up plugs of thick mucus (containing hyphae and 
eosinophils)
Positive Aspergillus precipitins or raised Aspergillus IgG titre
Atopic (non-fungally 
atopic) asthmatic
All the following are required
Physician diagnosed asthma
No diagnosis of aspergillosis
Negative SPT (at 3 mm cut-off ) and/or IgE (<0.4) to all fungi tested, including Alternaria alternata, Candida albicans, Clad-
osporium herbarum, Penicillium notatum, Trichophyton rubrum, A. fumigatus
Positive SPT (at 3 mm cut-off ) and/or IgE (<0.4) to any allergen non-fungal allergen tested (e.g. mite, cat, dog and grasses)
Note Only SPT or IgE need be completed, but if both are done and one is positive this is classed as a positive result
Non-atopic asthmatic All the following are required
Physician diagnosed asthma
No diagnosis of aspergillosis
Negative SPT (at 3 mm cut-off ) and/or IgE (<0.4) to all allergens tested, including mite, cat, dog and grasses
Negative SPT (at 3 mm cut-off ) and/or IgE (<0.4) to all fungi tested, including Alternaria alternata, Candida albicans, Clad-
osporium herbarum, Penicillium notatum, Trichophyton rubrum, A. fumigatus
Note: Only SPT or IgE need be completed, but if both are done and one is positive this is classed as a positive result
Healthy control All the following are required
No diagnosis of asthma
No diagnosis of aspergillosis
Negative SPT (at 3 mm cut-off ) and/or IgE (<0.4) to all allergens tested, including mite, cat, dog and grasses
Negative SPT (at 3 mm cut-off ) and/or IgE (<0.4) to all fungi tested, including Alternaria alternata, Candida albicans, Clad-
osporium herbarum, Penicillium notatum, Trichophyton rubrum, A. fumigatus
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change, and that the time points of 0–3, 6 and 9  h are 
representative of exposure to conidia, germ tubes and 
hyphae respectively [31]. Experiments were repeated in 
triplicate.
Measuring expression by MDMs
The human innate and adaptive immune responses RT2 
profiler PCR array (SABiosciences) was used to measure 
expression of various genes related to those we genotyped 
in pooled RNA samples (1 μg) from each disease group 
(n = 10 subjects) using HRPT1, RPL13A and GAPDH as 
housekeeping normaliser genes. Arrays were repeated in 
triplicate. The investigated genes included TLRs (TLR1, 
2, 3, 4, 9, 10) and related receptors (TREM1) and intra-
cellular signalling genes (IRAK2, TRAF6, MYD88). For 
the majority of the arrays, the three housekeeping genes 
HRPT1, RPL13A and GAPDH were used as the normal-
izer genes, however, HPRT1 was found to be variable in 
the healthy 9 h samples and so only RPL13A and GAPDH 
were used for the normalization of this experiment. 
Results were available for only two replicates of the asth-
matic 6  h time point due to technical difficulties. The 
data was analysed using the manufacturer’s online data 
analysis tool (http://pcrdataanalysis.sabiosciences.com/
pcr/arrayanalysis.php) to calculate fold changes relative 
to a calibrator.
Statistical analysis
Statistical analysis was completed in Stata, SPSS (Version 
16; SPSS Inc.) and GraphPad Prism (Version 5.02; Graph-
Pad Software Inc.). Ages and % males were compared 
between the groups using Mann-Whitney tests as the 
data was not normally distributed. Expression data was 
analysed using T-tests and repeated measures one-way 
ANOVA, using data from the triplicate arrays. Standard 
deviation was calculated for these. Data for TLR1 was 
highly variable between replicates for the healthy group 
and this was excluded from analysis. As the one-way 
ANOVA required three replicates, the 6 h time point was 
excluded from this analysis of the asthma samples.
Results
Characteristics of study participants
The characteristics of the subjects recruited for genotyp-
ing are shown in Table 2. All are Caucasian. Those sub-
jects with ABPA tended to be older than other groups 
(p  <  0.0001), and had poorer lung function (%  pre-
dicted FEV1, %  predicted FVC or FEV1/FVC ratio, all 
p  <  0.0001) (Table  2). Of the 97 ABPA, 280 healthy, 
167 atopic asthmatic subjects recruited, 95 ABPA, 279 
healthy and 166 atopic asthmatic subjects were success-
fully genotyped.
The characteristics of the subjects selected for the gene 
expression study are shown in Table 3. The ABPA group 
were older than the healthy group (media age 59.5 years 
vs. 38.0 years, p = 0.0007), but not significantly different 
to the non-atopic asthmatic group (Table 3).
Multiple SNPs are associated with ABPA
All the p values (uncorrected and FDR corrected) for all 
the models tested can be seen in Additional file 1: Table 
S2. Of the 195 SNPs analysed (Additional file 1: Table S1), 
17 SNPs in nine genes were found to be associated with 
ABPA (p < 0.05, Table 4). Three of these survived correc-
tion for multiple testing (Table  4; Fig.  1). Compared to 
atopic asthmatics, ABPA patients were more likely to be 
carriers of the rare A allele of the exonic missense muta-
tion in IL13 (rs20541). They were also more likely to carry 
the common G allele and common GG genotype of the 
intronic SNPs in IL4R rs3024656 and TLR3 rs1879026, 
respectively. Further analysis found that four of the SNPs 
associated with ABPA on the ABPA vs. Atopic asthma 
model were also associated on the ABPA vs. Healthy 
model (Additional file 1: Table S3). These were Dectin-1 
rs7959451, IL13 rs1800925, IL4R rs3024656 and IL4R 
rs1029489. 
Expression of TLR genes varies little over time 
after stimulation with A. fumigatus
Expression of TLR2, TLR4, TLR6, and, to a lesser extent, 
TLR3, is lower in the ABPA and non-atopic asthmatic 
groups than in the healthy group at 6  h, and higher at 
9 h (Fig. 2a–d). For TLR2 and TLR4 expression at 9 h is 
also significantly higher in asthma than in ABPA. The dif-
ferences compared to the healthy group are a result of 
increased 6 h and reduced 9 h expression in the healthy 
subjects, which are not observed in the asthma or ABPA 
groups (Fig.  2e–h). The downstream signalling genes, 
TRAF6, IRAK2 and to a lesser extent MYD88 follow a 
similar expression pattern, although expression of other 
downstream signalling molecules does not (Additional 
file 1: Fig. S1). Expression of the activating receptor, trig-
gering receptor expressed on myeloid cells 1 (TREM1) 
is significantly reduced in the ABPA group at baseline, 
compared to both the asthmatic and healthy groups, and 
remains lower at all time points (Fig. 3), which may sug-
gest a reduced amplification of the TLR response in the 
ABPA group. Expression of further TLRs, including TLR9 
and TLR10 is shown in the (Additional file 1: Fig. S2).
Discussion
In the largest genetic association study of ABPA con-
ducted to date, we have identified associations with SNPs 
in three immune genes, IL13 (rs20541), IL4R (rs3024656) 
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and TLR3 (rs1879026), which remained significant after 
correction for multiple testing. Of these genes, only IL4R 
has previously been associated with ABPA; IL13 and 
TLR3 are novel candidate genes, which help to increase 
our understanding of the aberrant immune response 
occurring in ABPA patients. These associations now 
require replication in other populations to confirm their 
importance.
The association of SNPs in IL13 and IL4R with ABPA 
is interesting. IL13 and IL4 are Th2 cytokines and ABPA 
is known to involve a Th2 response [5]. PBMCs from 
ABPA  patients show increased Aspergillus-induced IL-5 
and IL-13 production, and decreased IFNγ production, 
compared to healthy controls [5]. Five SNPs in IL13 and 
IL4R were associated with ABPA before correction for 
multiple testing, and one in each remained significant 
after correction. One IL4R SNP has been previously 
associated with ABPA (rs1805010) [12]. This SNP has 
also been suggested to affect sensitivity to IL4 stimula-
tion [12]. Unfortunately, this SNP failed the genotyp-
ing QC in the current study, however, a different SNP in 
IL4R (rs3024656) was found to be associated with ABPA. 
RS1805010 is a missense SNP in located in the 5′UTR of 
the IL4R gene (position 16:27344882), while rs3024656 is 
intronic (position 16:27358288). There is a very low LD 
between them (r2 = 0.16).
IL13 and IL4 act via the IL4R receptor and are involved 
in the allergic response to antigens such as those pro-
duced by A. fumigatus [5]. It has been shown that poly-
morphisms in IL4R and IL13 can have synergistic effects 
Table 2 Characteristics of patients and controls recruited
IQR interquartile range
Characteristic ABPA Atopic asthma Healthy
n 97 167 280
Age (year) (median, IQR) 61.7 year (54.0–69.5) 50.1 year (43.8–64.9) 47.0 year (44.2–50.6)
% Male 53.6 % (52/97) 41.3 % 40.4 % (113/280)
Asthma (%) 88.7 % (86/97) 100 % (167/167) 0 % (0/280)
Lung function tests (n) 67 165 255
FEV1 % predicted (median, IQR) 64.0 (51.0–78.0) 96.0 (78.4–108.2) 107.5 (99.6–117.2)
FVC % predicted (median, IQR) 96.0 (87.5–106.5) 108.9 (99.0–118.5) 114.7 (105.6–123.6)
FEV1/FVC ratio (median, IQR) 56.0 (47.9–64.0) 72.0 (63.0–79.0) 79.0 (75.0–83.0)
Markers of ABPA
Bronciectasis (%) 67.0 % (65/97) N/A N/A
Total serum IgE (kU/L) (median, IQR) (n) 2250 (1100–4425) (96) N/A N/A
Aspergillus specific IgE (kUA/L) (median, IQR) (n) 9.7 (3.2–36.0) (62) N/A N/A
Table 3 Characteristics of patients and controls used for gene expression experiment
The recruitment criteria specified that the asthma control patients had a negative specific IgE or skin test to aspergillus. Therefore Aspergillus specific IgE level was not 
measured on every patient but was negative when measured
IQR interquartile range
Characteristic ABPA Non‑atopic asthma Healthy
n 10 10 10
Age (year) (median, IQR) 59.5 year (55.7–66.1) 46.0 year (37.4–57.3) 38.0 year (31.2–51.1)
% Male 40.0 % (4/10) 20 % (2/10) 40 % (4/10)
Asthma (%) 70 % (7/10) 100 % (10/10) 0 % (0/10)
Lung function tests (n) 5 9 N/A
FEV1 % predicted (median, IQR) 75.0 (71.0–80.0) 85.0 (58.0–105.0) N/A
FVC % predicted (median, IQR) 103.0 (102.0–106.0) 113.0 (89.0–116.0) N/A
FEV1/FVC ratio (median, IQR) 60.8 (55.0–63.4) 78.0 (46.0–81.0) N/A
Markers of ABPA N/A
Bronciectasis (%) 80 % (8/10) 50 % (5/10) N/A
Total serum IgE (kU/L) (median, IQR) (n) 4100 (2650–7075) (10) 71.9 (63.4–110.0) (10) N/A
Aspergillus specific IgE (kUA/L) (median, IQR) (n) 34.0 (2.9–60.3) (6) N/A N/A
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[36]. IL4 is a key cytokine required for differentiation of 
Th2 cells [26]. Uncontrolled Th2 are thought to be det-
rimental for both survival and disease progression in 
aspergillosis, and the identification of these SNPs sup-
ports this theory [17, 20, 37, 38].
The IL4R SNP (rs3024656) has been previously associ-
ated with only invasive squamous cell cervical cancer [39] 
and is not in high LD (r2  >  0.80) with any other SNPs, 
however, the IL13 SNP (rs20541) has been previously 
associated with many diseases and phenotypes, including 
asthma, atopy and serum IgE level [40–42]. In addition, 
rs20541 is in high LD with other SNPs (rs849, rs848, 
rs1295685, rs1295686) that have also been extensively 
associated with disease, including with asthma and serum 
IgE level [41]. As discussed, ABPA is an allergic disease 
often found in asthmatics, however, our use of atopic 
asthmatic controls should control for any association 
with asthma or non-fungal atopy in our population and 
suggests that this SNP is associated with ABPA or fungal 
atopy specifically. RS20541 is an exonic missense muta-
tion in IL13, which results in an codon change from CGG 
to CAG, and an arginine (R) to glutamine (Q) substitution 
rs 2 0 5 4 1 (IL 1 3 )
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Fig. 1 Genotype frequencies of SNPs associated with ABPA after correction for multiple testing
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at amino acid position 110. Compared to atopic asthmat-
ics, ABPA patients were more likely to be carriers of the 
rare A allele, coding for glutamine. This Q110 variant of 
IL13 appears to be less susceptible to clearance and more 
stable in plasma than the R110 variant, which may cause 
increased circulating levels in vivo [43]. This is supported 
by reports demonstrating significantly higher serum 
IL13 levels in human carriers of the Q110 homozygous 
genotype, compared to carriers of the R110 homozygous 
genotype [43]. As mentioned, Aspergillus-induced IL-13 
is increased in PBMCs from ABPA  patients compared 
to those from healthy controls [5]. The RS20541 A allele 
and the glutamine variant is also associated with elevated 
IgE levels [44]. IgE levels are also raised in ABPA [6]. In 
addition to rs20541, another SNP in IL13 (rs1800925) 
was found to be associated with ABPA, although this 
association did not survive correction for multiple test-
ing. Like rs20541, IL13 rs1800925 has been extensively 
associated with atopic disease, including asthma, psori-
atic arthritis and eczema [40, 42, 45, 46], as well as with 
allergy and IgE levels [42, 47]. It has also recently been 
associated with COPD [48]. The T allele of this SNP was 
associated with ABPA in the current study. This allele has 
been demonstrated to increase IL13 promoter activity in 
primary human and murine CD4 + Th2 cells by creation 
of a Yin-Yang binding site, which overlaps a STAT motif 
[49]. STAT6-mediated repression of IL13 transcription 
is reduced, allowing increased promoter activity and 
increased IL13 expression [49]. In addition, mitogen-acti-
vated PBMCs from humans homozygous for the T allele 
have been shown to secrete significantly higher levels of 
IL13 compared with those from CC and CT individuals 
[49]. The TT genotype is also associated with increased 
cord blood IgE [47]. The A allele (glutamine) of rs20541 
and the T allele of rs1800925 may increase susceptibil-
ity to ABPA by increasing IL13 expression and increas-
ing the allergic Th2 response, including IgE production, 
which is detrimental in aspergillosis. Other SNPs in IL13 
and in other Th2 cytokines and receptors such as IL4 and 
IL4R could increase susceptibility to ABPA in a similar 
way.
Toll like receptors (TLRs) are known to be important 
in the recognition of A. fumigatus and as such it is likely 
that mutations in these receptors will influence suscepti-
bility to aspergillosis. Traditionally, the most studied are 
TLR2, TLR4 and TLR9, however, recent work suggests 
that other TLRs such as TLR1, TLR3 and TLR6 may also 
be important [17–22]. Two SNPs in TLR1 (rs5743611, 
rs4833095) have been previously associated with IA, and 
one SNP in TLR9 (rs5743836) has been previously asso-
ciated with ABPA [13, 22]. The study that identified the 
TLR9 SNP was small, involving only 22 ABPA patients 
and 88 controls [13]. None of these SNPs was found to be 
associated with ABPA in the current study; however, we 
TREM1





























Fig. 3 Expression of TREM1 by MDMs from ABPA, asthmatic and healthy subjects (n = 10, pooled). a shows expression in the ABPA (black bars) 
and asthma groups (grey bars) relative to the healthy group (dotted line) at each time point. Stars indicate significant differences between ABPA 
and asthma, calculated by t-test. b shows expression in ABPA (open circles), asthmatic (closed squares) and healthy (closed triangles) subjects over 
time, relative to asthma 0 h. Stars indicate significant changes over time, calculated by repeated measures 1-way ANOVA. *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001. Bars indicate standard deviation of the three replicates
(See figure on previous page.) 
Fig. 2 Expression of TLRs by MDMs from ABPA, asthmatic and healthy subjects (n = 10, pooled). a–d show expression in the ABPA (black bars) 
and asthma groups (grey bars) relative to the healthy group (dotted line) at each time point. Stars indicate significant differences between ABPA 
and asthma, calculated by t-test. e–h show expression in ABPA (open circles), asthmatic (closed squares) and healthy (closed triangles) subjects over 
time, relative to asthma 0 h. Stars indicate significant changes over time, calculated by repeated measures 1-way ANOVA. *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001. Bars indicate standard deviation of the three replicates
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did identify five SNPs at various locations within TLR3 
as associated with ABPA. Only one of these (rs1879026) 
survived correction for multiple testing. This is an 
intronic SNP that has not been associated with disease in 
the past and is not in high LD (r2 > 0.80) with any other 
SNPs. TLR3 has only recently been implicated as a recog-
nition receptor for A. fumigatus, with studies identifying 
a role in epithelial cell mediated protection against this 
fungus [19, 50], and the discovery of this association with 
ABPA is helpful in supporting this role.
We also analysed the expression of many of the TLR 
genes known to be expressed on human macrophages, 
in MDMs from healthy subjects, non-atopic asthmatics 
and ABPA subjects, in response to stimulation with A. 
fumigatus. As has been described by previous groups, we 
only observed small changes in gene expression over time 
after stimulation with A. fumigatus [19, 21, 23], however, 
9  h TLR2 and TLR4 expression was significantly lower 
in the ABPA group compared to the asthmatic group. 
This could represent a differential response to the hyphal 
form of the fungus (predominant at the 9 h time point), 
or a differential time-dependant response to 9  h of cul-
ture. However, as the fold changes are low, it may also be 
that these differences and patterns are not biologically 
relevant. In addition, it may be that downstream signal-
ling and the response to this is more important in the 
response to fungus than any change in TLR expression. 
This may account for the small changes in expression 
observed in the current study as well as in previous stud-
ies [19, 21, 23]. Alternatively, as the expression of some 
downstream signalling molecules follows a similar pat-
tern to expression of the TLRs, there may indeed be a 
deficient response in the ABPA group.
The activating receptor TREM1 is found on neutro-
phils and monocytes and acts to amplifies inflamma-
tion induced by stimulation of TLRs, including TLR2 
and TLR4 [51, 52]. Expression of TREM1 is reduced in 
the ABPA group, which may indicate a reduced abil-
ity to respond to TLR stimulation, including stimula-
tion by fungi such as A. fumigatus. As TLR2 and TLR4 
are key in the response to A. fumigatus, it could be that 
TREM1 plays a role in the response to A. fumigatus via 
interactions with these. We recently reported increased 
TREM1 expression by MDMs from CCPA subjects com-
pared to those from healthy controls, and suggested that 
this might be an attempt to combat reduced baseline 
expression of TLRs by the CCPA group [32]. This does 
not appear to be the case in ABPA; in this situation, 
baseline TLR expression is not reduced, and increased 
TREM1 expression is not observed. Although both ABPA 
and CCPA occur in overtly immunocompetent subjects, 
they are very different diseases; CCPA is not consid-
ered an allergic disease and is not related to asthma. It 
is therefore not surprising that increased TREM1 expres-
sion is observed in MDMs from CCPA and reduced 
TREM1 expression is observed in ABPA. It is, however, 
interesting and suggests that this previously unstudied 
molecule may be important in susceptibility to fungal 
diseases and may benefit from further study.
We do not have information about the specific treat-
ments patients were receiving at the time that blood 
was collected, however, because a small proportion of 
patients with ABPA in our clinic are prescribed corti-
costeroid therapy, either continuously or intermittently, 
it may be that some of those tested are currently taking 
this medication. The same is true for the asthmatic popu-
lation. Systemic corticosteroid treatment can influence 
cell proliferation and RNA expression [53], however, as 
this effect of steroids on cells is temporary, we would 
expect any effect to be lost after the freezing, thawing and 
15 days of culture that these cells undergo prior to use in 
our experiments.
While there remains uncertainty about the relevance of 
the expression profiles observed for the TLR genes, the 
association of the SNP in TLR3 with ABPA supports a 
role for this receptor in recognition of A. fumigatus and 
in response to this and TLR3 may affect susceptibility 
to ABPA, with SNPs that reduce the fungal recognition 
leaving people more susceptible to this disease.
We acknowledge that the alveolar macrophage could be 
considered as the ideal cell type in which to study inter-
actions between host and pathogen as the initial inter-
actions in the host are likely to occur within the lungs. 
However, if we had recruited only subjects that were fit 
for bronchoscopy we would have skewed the study popu-
lation in favour of patients with mild ABPA. Collection 
of blood is a much less invasive procedure and is possible 
for subjects with all severities of ABPA; the use of MDMs 
therefore prevents population skewing.
We opted to use pooled samples for our gene expres-
sion work as although this prevents analysis of inter-
patient variability, it allows for analysis of a greater 
number of genes (due to limited availability of patient 
cells). As has been discussed in detail previously [31], 
mean values for cases and controls are likely to be 
broadly similar to the results of pooled samples, however, 
we acknowledge the possibility that our pooled value 
could be skewed by a minority of individuals, Unfortu-
nately, pooling also prevented us from associating gene 
expression with individual genotypes and therefore from 
identifying functional consequences of the SNPs. In addi-
tion, we felt that in the smaller gene expression study, the 
use of atopic asthmatic controls such as those used in the 
genetic association study, could present a risk as results 
could be skewed due to association with atopy to another 
non-fungal allergen (if two or three of the small control 
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group were atopic to the same allergen), and so opted for 
non-atopic controls. In the genetic study, the larger con-
trol group with lots of different allergic profiles meant 
this was less likely to be a problem. We understand this is 
primarily a hypothesis generating study and further work 
will be required.
In addition, we acknowledge that the controls within 
our study are older than the cases, and this may mean 
that some controls may go on to develop ABPA later in 
life. This would reduce (rather than increase) our power to 
find associations with ABPA, and as such does not invali-
date our findings. As a hypothesis generating study, and 
we appreciate that future work is required to support our 
results. This work will include replication of the genetic 
associations, functional work and experiments to confirm 
that gene expression differences translate to differences 
in protein levels. Despite this, we believe our results are 
important in suggesting novel genes and pathways that are 
associated with ABPA susceptibility and may be involved 
in the pathogenesis of ABPA. We hope these results are 
useful in providing novel directions for future research.
Conclusions
The genetic association study presented here is the most 
extensive study into genetic susceptibility to ABPA to 
date, involving three times as many patients as most pre-
vious studies and investigating many more SNPs. We 
have identified SNPs in candidate genes including TLR3, 
IL4R and IL13 that are associated with ABPA, and which 
help to support the involvement of these previously theo-
rised receptors and pathways in the immune response to 
A. fumigatus and in susceptibility to ABPA. We hope that 
this increased understanding will in future lead to devel-
opments in the treatment and diagnosis of ABPA.
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